Diabetes is a major global and local health problem.
Diabetes currently affects 529 million people worldwide.
>38 million people in the U.S. have diabetes.
98 million adults in the U.S. have pre-diabetes.
There are no current oral medications for Type 1 diabetes.
To stay alive, individuals with Type 1 diabetes require multiple daily insulin injections and/or continuous insulin infusion.
None of the current oral medications address the problem of excessive glucagon levels associated with diabetes.
Approved treatments are also urgently needed for metabolic dysfunction–associated steatotic liver disease (MASLD) (previously non-alcoholic fatty liver disease), which is often associated with diabetes.
No specific drug is available to inhibit TXNIP (thioredoxin-interacting protein), a newly identified therapeutic target.
TIXiMED offers a solution – TIX100.
TIXiMED is the exclusive license holder for the underlying patent (composition of matter and method of use) surrounding the TIX100 small molecule.
How TIX100 Works
The TIX100 Advantage
Strong, peer-reviewed preclinical data (Thielen…Shalev, Cell Metabolism 2020)
TIX100 is more effective, more specific, and up to 100-times more potent in inhibiting TXNIP than verapamil
TIX100 specifically targets TXNIP. This approach has successfully been translated to humans with T1D – see verapamil trials, (Ovalle…Shalev, Nature Med 2018, Xu…Shalev, Nature Comm 2020) and independently validated (CLVer trial, JAMA 2023)
Four sets of animal models and human islet studies indicate TIX100 efficacy
TIX100 is taken orally. By contrast, subjects with T1D need insulin given by multiple daily subcutaneous injections or an infusion to survive, and no oral medications are available.
TIX100 targets the underlying causes of the disease. It brings the elevated TXNIP levels back down into the normal range, protects beta cell insulin production, and inhibits the excessive secretion of glucagon typically seen in diabetes. (Glucagon counters the effects of insulin, making the blood sugar go even higher.) By doing so, TIX100 is also expected to be effective in the face of insulin deficiency.
Unlike current experimental glucagon receptor antagonist drugs, TIX100 lowers serum glucagon levels, reduces blood lipids, and protects against fatty liver, suggesting that it may also be effective in the context of MASLD or metabolic dysfunction–associated steatohepatitis (MASH).